Boehringer Ingelheim Canada Expands 'Detect the SOS' to Tackle Undiagnosed Heart and Kidney Risks
Event summary
- Boehringer Ingelheim Canada extends its global 'Detect the SOS' initiative to Canada to address underutilization of uACR testing for cardiovascular and kidney risk assessment.
- Only 13% of Canadians with diabetes receive annual uACR and eGFR testing, despite guidelines recommending it for high-risk populations.
- Partnership with HeartLife Foundation and Kidney Foundation of Canada aims to raise awareness and improve early detection of hidden cardiovascular risks.
- uACR testing can identify early vascular damage, with elevated levels correlating to significantly higher risks of heart failure, stroke, and cardiovascular death.
The big picture
Boehringer Ingelheim Canada's expansion of the 'Detect the SOS' initiative underscores the critical gap in early cardiovascular and kidney risk detection. With over 50% of at-risk Canadians missing vital uACR testing, this partnership aims to bridge the diagnostic divide. The campaign aligns with broader industry trends toward preventive healthcare and personalized risk management, particularly in chronic disease populations.
What we're watching
- Awareness Impact
- Whether the campaign can significantly increase uACR testing rates among Canadians with hypertension or type 2 diabetes.
- Clinical Outcomes
- How earlier detection through uACR testing translates into improved cardiovascular and kidney health outcomes.
- Regulatory Influence
- The pace at which healthcare guidelines may evolve to mandate uACR testing for high-risk populations.
Related topics